Navigation Links
Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
Date:12/14/2007

ith serious autoimmune and inflammatory conditions."

Alba will lead worldwide development operations through the end of Phase 2 clinical trials in Celiac disease. The companies will share responsibility for Phase 3 clinical trial execution and for the pursuit of additional indications such as Crohn's disease. This will leverage Shire's regulatory and clinical experience, as well as its commercial infrastructure.

Michael Yasick, Shire's Senior Vice President and Gastrointestinal Global Business Unit Leader added:

"We are excited about this opportunity for Shire to expand its GI franchise beyond mesalamine-related products such as Lialda(TM) / MEZAVANT XL(R). We look forward to working closely with Alba on the development of these new therapies."

Dr. Paterson also noted that, "this partnership is another step in Alba's evolution as a biopharmaceutical company and provides a significant validation of our barrier function technology platform, specifically applied to gastrointestinal disease. The partnership will also enhance our ability to provide solutions for other inflammatory and immune related diseases, both acute and chronic."

About AT-1001

AT-1001 is an inhibitor of barrier dysfunction that has been shown to block intestinal permeability and the genesis of some autoimmune diseases, both through the reduction of antigen presentation to the body's immune system and the inhibition of cytokine production. AT-1001 is orally formulated and is currently in Phase 2 studies for Celiac disease, a gastrointestinal autoimmune disease. INDs for oral AT-1001 in beta cell preservation (Type 1 Diabetes) and Crohn's disease have also been filed and cleared FDA review.

About Alba

Alba Therapeutics Corporation is a privately held, clinical-stage biopharmaceutical company based in Baltimore, Maryland. Alba is dedicated to development and commercialization of disease modifying therapeutics to treat autoimmune and inflammatory di
'/>"/>

SOURCE Alba Therapeutics Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... Baylor Research Institute (BRI) at ... Institute (TGen) in Phoenix, AZ , ... detection and treatments for patients with a broad range of ... to new clinical trials and access to technology to drive ... bench to bedside across Baylor Scott & White ...
(Date:5/21/2015)... Seventh Wave Laboratories, a consulting-based contract ... pharmaceutical products and medical devices, announced the purchase of ... 50,000 sq. ft. building more than three times the ... Facility renovations will begin immediately and the gradual transition ... in September. , “We are excited about this ...
(Date:5/21/2015)... , May 21, 2015  Susan Hedstrom, Executive ... a nonprofit organization dedicated to supporting research to ... (PWS), announced today that FPWR has received the ... Irina Shaulov contributed $1 million in support ... "Our gift ...
(Date:5/21/2015)... San Francisco, CA (PRWEB) May 21, 2015 ... microbiome sequencing, has announced a partnership with PicnicHealth, ... records for patients. Participants diagnosed with Inflammatory Bowel ... as well as a complementary uBiome research kit. ... Summer 2014. , For more ...
Breaking Biology Technology:Precision Medicine Collaboration to Increase Options for Cancer Patients 2Precision Medicine Collaboration to Increase Options for Cancer Patients 3Precision Medicine Collaboration to Increase Options for Cancer Patients 4Seventh Wave Laboratories Purchases Building for Expansion, Upcoming Move 2Seventh Wave Laboratories Purchases Building for Expansion, Upcoming Move 3The Foundation for Prader-Willi Research Receives $1M Contribution in Support of Clinical Initiatives 2uBiome Partners with PicnicHealth 2uBiome Partners with PicnicHealth 3
... Contaminations of cell cultures show severe problems in the research ... turns here particularly to the prevention , ... that develop substances for therapeutic applications ... focus., Endotoxins (Lipopolysaccharides, LPS) are biologically active, ...
... Amino Acids, RP-HPLC, Precolumn derivatisation, o-Phthalaldehyde (OPA), 2-Mercaptopropionic acid, ... Introduction: , ... light in the UV/visible spectrum. In order to increase sensitivity, ... the amino acids react with a precursor to yield ...
... and specific PCR on any thermal cycler , ... unrivaled performance of , HotStarTaq Plus DNA Polymerase with ... thermal cycler. , , ... Ultrafast hot-start PCR time savings of up to 75%, ...
Cached Biology Technology:Endotoxins and their Relevance in R&D ApplicationsLPS Detection & Removal Methods 2Endotoxins and their Relevance in R&D ApplicationsLPS Detection & Removal Methods 3Endotoxins and their Relevance in R&D ApplicationsLPS Detection & Removal Methods 4Endotoxins and their Relevance in R&D ApplicationsLPS Detection & Removal Methods 5Endotoxins and their Relevance in R&D ApplicationsLPS Detection & Removal Methods 6Endotoxins and their Relevance in R&D ApplicationsLPS Detection & Removal Methods 7ANALYSIS OF AMINO ACIDS BY REVERSED PHASE CHROMATOGRAPHY WITH PRECOLUMN DERIVATISATION AND UV/VISIBLE DETECTION 2ANALYSIS OF AMINO ACIDS BY REVERSED PHASE CHROMATOGRAPHY WITH PRECOLUMN DERIVATISATION AND UV/VISIBLE DETECTION 3QIAGEN Fast Cycling PCR Kit 2QIAGEN Fast Cycling PCR Kit 3QIAGEN Fast Cycling PCR Kit 4
(Date:5/11/2015)... 11, 2015  Synaptics Incorporated (NASDAQ: SYNA ... today announced the appointment of Wajid Ali ... Officer, reporting to Rick Bergman , President ... Financial Officer, Kathleen Bayless , who announced ... Mr. Ali brings extensive financial management expertise to ...
(Date:5/11/2015)... -- Curemark LLC, a privately held drug research and ... III double blind, randomized, placebo-controlled clinical trial to examine ... children ages 3-8 with Autism. Previously, Curemark announced the ... clinical trial for CM-AT in children ages 3-8 with ... chymotrypsin. This new trial will help determine whether all ...
(Date:5/8/2015)... SAN JOSE, Calif. , May 8, 2015 ... human interface solutions, today announced that members of the executive ... J.P. Morgan 43rd Annual Technology, Media and Telecom Conference ... Westin Waterfront Hotel in Boston, MA ... Date: May 27, 2015 Time: 2:45pm ET Location: The New ...
Breaking Biology News(10 mins):Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2Synaptics to Present at Upcoming Investor Conferences 2
... For Immediate Release The Scripps Research Institute and ... Medicine have been awarded approximately $7.5 million over five ... drug candidates for the treatment of nicotine dependence, and ... million will go to Scripps Research, $2.5 million to ...
... of Guelph researchers have finally figured out why female ... nothing to do with genes and everything to do ... "Their behaviour is overwhelmingly influenced by opportunity," said ... professor Andrew McAdam and a team of researchers from ...
... what goes missing in human cells when the gene that ... Johns Hopkins scientists have discovered a potential strategy for therapy. ... snippets known as microRNAs is dramatically reduced in human pancreatic ... a study published Dec. 15 in Genes and Development ...
Cached Biology News:Team awarded $7.5 million to identify potential drug candidates to treat nicotine addiction 2Team awarded $7.5 million to identify potential drug candidates to treat nicotine addiction 3Opportunity leads to promiscuity among squirrels, study finds 2Missing molecules hold promise of therapy for pancreatic cancer 2Missing molecules hold promise of therapy for pancreatic cancer 3
The Spheroplast Kit contains qualified reagents for the preparation of yeast spheroplasts. The reagents have been optimized for use with Pichia pastoris and are guaranteed to generate 70% spheroplast...
...
...
Recombinant Rat Fas Ligand/TNFSF6...
Biology Products: